Biosimilars—cheaper copies of complex biologic drugs—have started flooding the market, and the FDA has been actively removing regulatory hurdles to speed their approval and lower drug costs. A major wave has already arrived, with more widely prescribed medicines about to face competition from these lower-cost alternatives. The real question now is whether this momentum holds or gets derailed by policy shifts and the messiness of how America's healthcare system actually works. The event brought together people positioned to see where this goes next: Thomas Newcomer from Samsung Bioepis (a major biosimilar maker), rheumatology advocates concerned about patient access, independent healthcare consultants, and Ed Silverman from STAT covering the pharma beat. Their discussion centered on whether biosimilars have hit an inflection point—the moment when they stop being a niche story and become genuinely disruptive to drug pricing—or whether structural problems in the U.S. healthcare system will limit their real-world impact on what patients and insurers actually pay. The tension here matters because biosimilars theoretically should drive down costs for some of the most expensive drugs people take, especially biologics used for cancer, autoimmune diseases, and other serious conditions. But getting from FDA approval to actual savings requires navigating rebate systems, insurance formularies, hospital purchasing decisions, and reimbursement policies that don't always reward cheaper options. The speakers were essentially wrestling with whether the regulatory wins the FDA has notched actually translate to the kind of market disruption that changes how Americans access and afford these drugs.